Clinical Trial Update: A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing BMS-986393 to standard regimens in adults with relapsed or refractory and lenalidomide-exposed multiple myeloma; currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BMS-986393

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Status: RECRUITING